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Objective: To determine the prevalence of multidrug-resistant tuberculosis (MDR-TB)
among previously treated TB patients in Khyber Pakhtunkhwa (KP) Province, Pakistan.
Design and settings: A cross-sectional study was conducted (January–September 2009) in 10
districts of KP. All Category (CAT) I and CAT II failures, and CAT II relapse cases were
recruited within 1 week following declaration of treatment outcome or re-registration of
CAT II. Clinical information and sputum was collected from each patient.
Results: Total 139 patients were enrolled. Mycobacterium tuberculosis bacilli (MTB) was iso-
lated in 113 (81.3%) samples; Mycobacterium other than tuberculosis (MOTT) was isolated
in 7 (5%) samples. MDR-TB was noted in 66 (58.4%) patients and extensive drug resistant
(XDR-TB) in 2 (1.8%) patients. Amongst MDR patients, 20 (62.5%) were CAT I failure, 19
(76%) CAT II failure and 27 (48.2%) CAT II relapse cases. Resistance to Isoniazid was most
common in 84 (74%) cases, followed by Pyrazinamide in 73 (64.6%) cases, Rifampicin in
67 (59%) cases, Streptomycin in 60 (53%) cases, Ethambutol in 58 (51%) cases, and Ofloxacin
in 18 (22.2%) cases.
Conclusion: High rate of drug resistance, including MDR observed among failures and
relapse cases. This study emphasizes the need to review TB care delivery, particularly in
failure cases in difficult regions such as KP that have seen considerable population dis-
placement and conflict in recent years.
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Introduction
Tuberculosis (TB) is a major public health problem, with 9.4
million new cases and 1.7 million deaths each year worldwide
[1]. Pakistan with an annual incidence rate of 231/100,000
population and a prevalence rate of 355/100,000 population,
ranks 8th in the estimated global TB burden list [1,2]. Pakistan
is one of the 27 high multidrug-resistant MTB (MDR MTB) bur-
den countries with estimates of 2.9% MDR in untreated and
35.4% amongst previously treated TB patients [3]. The emer-
gence of MDR-MTB, i.e. resistance to at least Rifampicin and
Isoniazid associated with treatment failure, relapse, compli-
cations and mortality, presents additional challenges in TB
control [4,5]. The response of patients with MDR-MTB to other
first-line anti-tuberculosis treatment (including Pyrazinamide
and Ethambutol) is poor and results in high case fatality rates.
Treatment of these patients with second-line drugs is on the
other hand expensive and toxic, often requiring hospitaliza-
tion for the management of complications arising as a result
of the therapy used and its side effects [4,6,7]. Management of
MDR cases, therefore, adds additional constraints onto the
limited health care resources of developing countries [8,9].
Moreover, emergence of extensive drug resistant TB (XDR-
TB) further complicates treatment with reduced efficacy of
available anti-tuberculosis drugs [10–12]. Poor compliance
with DOTS guidelines and inadequate care delivery resulting
in treatment failure and relapse is a major cause of drug resis-
tance in tuberculosis [3,4].
While a limited number of studies on drug resistance in
tuberculosis have been carried out in laboratory settings,
prevalence of MDR-TB among previously treated TB cases in
Pakistan is unreported [10,13,14]. Such information would be
useful not only to estimate the extent of the problem in this
high-risk population, but also for reviewing the tuberculosis
control program and for developing the necessary steps for
preventing the spread of MDR-TB in the country. TB care is
particularly challenging in the Khyber-Paukhtunkhwa prov-
ince (KP), which harbors internally displaced persons and
has a long history of conflict. A study was therefore con-
ducted to determine the prevalence of MDR TB among previ-
ously treated TB cases, i.e., failure cases of CAT I and failure
cases and relapses of CAT II patients in KP.
Materials and methods
A cross-sectional study was conducted in KP province of Paki-
stan from January 2009 to September 2009. KP province bor-
ders Afghanistan to the north-west, Gilgit-Baltistan to the
north-east, Azad Jammu and Kashmir to the east, the Feder-
ally Administered Tribal Areas (FATA) to the West and South,
Baluchistan to the south and Punjab and the Islamabad Capi-
tal Territory to the south-east. The main ethnic groups in the
KP province are the Pashtuns, locally referred to as Pakhtuns,
who form about two-thirds of the population, followed by a
number of smaller ethnic groups, most notably, the Hindko-
wans. The KP province has an estimated population of roughly
21 million, excluding the 1.5 million Afghan refugees and their
descendants in the province [15]. Pulmonary tuberculosis pa-tients fulfilling the World Health Organization (WHO) diagnos-
treatment for TB) and CAT II (retreatment of, relapse, treat-
ment failure, smear positive who have taken anti-tuberculosis
treatment (ATT) for more than one month and defaulted) [16]
were recruited from 10 selected districts of KP. Selection of the
10 districts was based on the frequency of failure cases of CAT
I and CAT II patients during 2006 and during the first half of
2007, availability of a reachable Aga Khan University (AKU)
collection point and the prevailing security situation. Failure
cases were selected within 1 week by District TB Officers
(DTO)/Directly Observed Therapy Short course (DOTS) facilita-
tors of the diagnostic unit. During a period of 9 months, spu-
tum was collected from all CAT I failure cases and CAT II
failure and relapse cases within 1 week after the declaration
of treatment outcome or re-registration of CAT II patients.
Early morning sputum specimens were collected from the pa-
tients and transported to the nearest AKU collection point as
soon as possible. In case of delay, the sputum samples were
stored in a refrigerator and transported within 24 h. Drug
resistance testing for anti-tuberculosis drugs was performed
according to standard Clinical Laboratory Standard Institute
(CLSI) guidelines [17]. Clinical information forms were filled
out by trained DOTS facilitators, the District TB Officers
(DTO) or the treating physician. Adequate training was given
to the staff through the Provincial TB Control Program (PTP)
with the involvement of the respective regional TB control
program officers. Information was collected for district, sex,
age, weight, marital status, education, occupation, number
of person living in the family, any person with TB in the family,
clinical history and treatment history.
Laboratory methods
Sputum samples were decontaminated using N-acetyl-L-cys-
teine (NALC) sodium hydroxide and then concentrated using
centrifugation (3000·g) for 30 min. Sediment was used for
AFB microscopy and culture. Smears for microscopy were
screened using Auramine staining, and positive slides were
confirmed by Kinyoun modification of Ziehl Neelsen stain
[18]. Lowenstein Jensen (LJ) medium (Oxoid) and MGIT were
used for culture. For LJ slant 0Æ2 ml of concentrated specimen
was inoculated and incubated for up to 8 weeks or until posi-
tive if earlier. MGIT vials were inoculated with 0Æ5 ml of spec-
imen and incubated at 37 C after supplementation of
medium with PANTA; containing Polymyxin B, Amphotericin
B, Nalidixic acid, Trimethoprim and Azlocilin. Growth index
of inoculated vials was checked for up to 8 weeks or until po-
sitive earlier. Growth from the positive LJ slant, and MGIT
vials were first stained with Kinyoun and Mycobacterium tuber-
culosis identified by BACTEC NAP TB differentiation test (Bec-
ton Dickinson, USA). Nitrate reduction and Niacin positivity
were also determined [19]. Susceptibility testing was per-
formed using an agar proportion method on enriched Middle-
brook 7H10 medium (BBL) at the following concentrations;
Rifampicin 1 lg/ml and 5 lg/ml, Isoniazid 0Æ2 lg/ml and 1 lg/
ml, Streptomycin 2 lg/ml and 10 lg/ml, Ethambutol 5 lg/ml
and 10 lg/ml, Ethionamide 5 lg/ml, Capreomycin 10 lg/ml,
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Pyrazinamide sensitivity was carried out using the BACTEC
7H12 medium pH6Æ0 at 100 lg/ml (BACTEC-TM PZA test med-
ium, Becton Dickinson, USA). MTB H37Rv was used as a con-
trol with each batch of susceptibility testing. For purposes of
this study, the following concentrations were used for analy-
sis; Rifampicin 1 lg/ml, Isoniazid 0Æ2 lg/ml, Streptomycin
2 lg/ml, and Ethambutol 10 lg/ml.
MDR-TB was defined as M.tuberculosis strains with resis-
tance to at least Isoniazid and Rifampicin. XDR-TB was de-
fined as MDR-TB with additional resistance to Ofloxacin and
at least one of the following injectable drugs: Kanamycin,
Capreomycin, or Amikacin. Drug-resistant tuberculosis is de-
fined as Mycobacterium tuberculosis bacilli (MTB) resistant to
one or more first line anti tuberculosis drugs. These include
Rifampicin (R), Isoniazid (H), Ethambutol (E), Streptomycin
(S) and Pyrazinamide (Z). Failure case is defined as a patient
who is started on re-treatment regimen after having failed
previous treatment. Relapse case is defined as a patient previ-
ously treated for TB who has been declared cured or treat-
ment completed, and is diagnosed with bacteriologically
positive (smear or culture) tuberculosis [16].
Data management and analysis
Data was entered in the Microsoft Excel (database) and then
transported to SPSS version 16 for analysis. Means (±SD) were
calculated for normally distributed quantitative variables;
median with inter-quartile ranges (IQR) was reported for
quantitative variables with unknown distribution. Frequen-
cies with (%) were computed for categorical variables. Preva-
lence of MDR pulmonary tuberculosis was calculated
separately in all failure categories. To evaluate the associa-
tion between MDR-TB status and all of the categorical patient
and environmental factors, chi-square test of independence
was applied, and for continuous variables (age and weight)
t-test applied. If chi-square and t-test showed significant
associations (p-value < 0.05), then strength and direction of
the association was determined through logistic regression
technique.
Results
A total of 139 patients were enrolled in the study. MTB was iso-
lated in 113 (81.3%) patients; mycobacterium other than tuber-
culosis (MOTT) in seven (5%) patients; while 19 (13.7%) were
culture negative. All patients with culture proven MTB were in-
cluded (Table 1). These included 32 (28.3%) CAT I failure pa-
tients, 25 (22.1%) CAT II failure patients and 56 (49.6%) CAT II
relapse patients. The mean age of study subjects was 31.3
(±14.7) with a male to female ratio of 1.05. The majority
(61.5%) of the subjects were married and only 29.5% had re-
ceived primary education. The unemployment rate was high
at 84.5%; and the majority of the patients came from large fam-
ilies, with 49.1% reporting other TB patients in their families.
MDR MTB was noted in 66/113 patients, including 20 CAT I
failure, 19 CAT II failure and 27 CAT II relapse cases. Resis-
tance to Isoniazid (H) was seen most frequently in 74% of
the patients, followed by resistance to Pyrazinamide (Z) in64.6%, Rifampicin (R) in 59%, Streptomycin (S) in 53% and Eth-
ambutol (E) in 51% of cases (Table 2). Resistance to Ofloxacin
was seen in 22.2% of the TB strains. Resistance to Kanamycin,
Amikacin, Capreomycin and Ethionamide was not detected in
CAT I failure patients. MDR plus Fluoroquinolone resistance
was observed in 18/113 cases. Only two (1.8%) isolates were
XDR MTB (Table 2).
No significant difference was observed in the drug resistant
patterns of CAT I failure and CAT II failure. Marginal statistical
significance was observed for Isoniazid (p-value; 0.067) and Pyr-
azinamide (p-value; 0.091) between CAT I failure and CAT II re-
lapse cases. On the other hand, significantly higher resistance
was noted for Isoniazid (p-value; 0.007), Rifampicin (p-value;
0.029), Pyrazinamide (p-value; 0.024), and MDR
(p-value; 0.020) in CAT II failure as opposed to relapse cases (Ta-
ble 2). None of the demographic variable was found to be signif-
icantly associated with MDR status on chi-square and t-test,
therefore advanced measures i.e., Odds Ratio (OR) calculated
through logistic regression technique, were not reported here.
Discussion
An MDR-TB rate of 58% amongst failure and relapse cases is
in agreement with other studies carried out in the country
also showing high MDR prevalence linked to acquired drug
resistance [20–23]. These findings are also consistent with re-
gional studies reporting 47–56% MDR in previously treated pa-
tients [22–24].
The high resistance to Isoniazid in all three categories is
extremely concerning, and points to an increasingly limited
role of this essential drug in such patients. The high level of
Isoniazid resistance is however consistent with other studies
[20,21,24,25,27–30].It is encouraging, however, that resistance
to second line agents was not seen in CAT I patients. The
presence of fluoroquinolone resistance, included in 28% of
CAT I failures though alarming is consistent with a previous
study of AKUH [31]. Other regional studies have also reported
similar trends of increasing fluoroquinolone resistance in
MDR isolates [32,33].
In the study population, prevalence of drug resistance,
including multidrug resistance, was significantly higher
among failures as compared with relapse cases. The present
study findings of higher resistance among treatment failures
is consistent with other regional studies; a study from New
Delhi, India, observed 50% MDR in failure cases and a 27%
MDR strain in relapse cases [24]. Among retreatment patients,
higher resistance has also been reported among treatment
failures in Ahmedabad (70%) and Bangalore (78%) compared
with 50.7% and 50% in relapsed patients, respectively
[25,26]. These results underline the need for timely identifica-
tion of treatment failures by early referral for culture and sen-
sitivity testing and early initiation of appropriate treatment
with second-line drugs.
In this study, although statistical analysis was hampered
by the small sample size, MDR patients tended to have
lower education levels, higher unemployment rate, and report
overcrowding and presence of a TB contact within their fam-
ilies. This serves to highlight the at risk population requiring
additional support.
Table 1 – General characteristics of all culture positive TB subjects and comparison of characteristics of MDR and Non MDR
pulmonary tuberculosis cases (n = 113).
Patients characteristics Total (n%) MDR TB (n%) Non MDR TB (n%) p-value
113 (100) 66 (58.4) 47 (41.6)
Age (mean ± SD) 31.265 (14.69) 31.409 (14.702) 31.064 (14.849) 0.903
Weight (mean ± SD) 45.477 (11.24) 45.733 (11.773) 44.754 (10.598) 0.651
Gender
Female 55 (48.7) 32 (58.2) 23 (41.8) 0.962
Male 58 (51.3) 34 (58.6) 24 (41.4)
cMarital status
Single 40 (38.5) 22 (55) 18 (45) 0.212
Married 64 (61.5) 43 (67.2) 21 (32.8)
Education
No formal schooling 68 (60.2) 43 (63.2) 25 (36.8) 0.400
Primary 34 (30.1) 18 (52.9) 16 (47.1)
Secondary or higher 11 (9.7) 5 (45.5) 6 (54.5)
bCurrently employed
No 82 (84.5) 48 (58.5) 34 (41.5) 0.708
Yes 15 (15.5) 8 (53.3) 7 (46.7)
No. of persons in the family(mean ± SD) 10.48 (7.41) 10.65 (7.25) 10.4 (7.32) 0.664
aTB patient in family
No 55 (50.9) 34 (61.8) 21 (38.2) 0.454
Yes 53 (49.1) 29 (54.7) 24 (45.3)
Failure
Failure CAT I 32 (28.3) 19 (62.5) 11 (37.5) 0.055
Failure CAT II 25 (22.1) 19 (76) 6 (24)
Relapse CAT II 56 (49.6) 27 (48.2) 29 (51.8)
a n = 5 Missing.
b n = 16 Missing.
c n = 12 Missing.
Table 2 – Resistance pattern in different failure and relapse categories.
Drug Susceptibility Testing (DST) Total Failure CAT I Failure CAT II Relapse CAT II p-value
N (%) N (%) N (%) N (%)
113 (100) 32 (28.3) 25 (22.1) 56 (49.6)
Susceptible to all five first line drugs 21 (18.6) 5 (16.6) 1 (4) 15 (26.8) 0.017
Any resistance
Isoniazid 84 (74.3) 26 (81.2) 23 (92) 35 (62.5) 0.007
Rifampicin 67 (59.3) 20 (62.5) 19 (76) 28 (50) 0.029
Pyrazinamide 73 (64.6) 23 (71.9) 20 (80) 30 (53.6) 0.024
Ethambutol 58 (51.3) 18 (56.2) 14 (56) 26 (46.4) 0.426
Streptomycin 60 (53.1) 19 (59.4) 13 (52) 28 (50) 0.868
aOfloxacin 18 (22.2) 7 (28) 3 (13.6) 8 (23.5) 0.363
aKanamycin 2 (2.5) 0 (0) 1 (4.5) 1 (2.9) 0.752
aAmikacin 3 (3.7) 0 (0) 2 (9.1) 1 (2.9) 0.318
bEthionamide 1 (1.5) 0 (0) 0 (0) 1 (3.7) 0.422
aCapreomycin 2 (2.5) 0 (0) 1 (4.5) 1 (3) 0.769
MDR 66 (58.4) 20 (62.5) 19 (76) 27 (48.2) 0.020
MDR + Fluoroquinolone 18 (15.9) 7 (21.9) 3 (12) 8 (14.3) 0.279
XDR 2 (1.8) 0 (0) 1 (4) 1 (7.1) 0.798
p-values are given for comparison of failure CAT II and Relapse CAT II cases.
a n = 23 For Failure CAT-I, n = 22 for Failure CAT-II, n = 34 for relapse CAT-II (except Capreomycin n = 22) and 81 for total (except Capreomycin
n = 80).
b n = 21 For failure CAT-I, n = 17 for failure CAT-II, n = 27 for relapse CAT-II and 67 for total.
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clinical suspicion and on therapeutic response to anti-tuber-
culosis drugs, rather than on the basis of culture isolation[29]. Such practices result in the inappropriate use of anti-
tuberculosis drugs and poor compliance with treatment. De-
spite TB having been declared a national emergency in 2001,
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hampered by under-developed health facilities and limited
resources. Regions such as Khyber Pakhtunkhwa face the
added challenge of interrupted patient access due to conflicts
and/or natural disasters.
Conclusion
This study, including all CAT I and CAT II failures, as well as
CAT II relapses registered in the study area and therefore rep-
resentative of the population, emphasizes the need to review
TB care delivery, particularly in failure cases in at risk popula-
tion particularly in difficult regions such as KP. This study also
emphasizes the importance of continuous monitoring of drug
resistance trends, which would be helpful in shaping future
policies to prevent the emergence and dissemination of MDR.Funding source
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